How we review

Last updated July 23, 2026.

This is the method behind every provider verdict on GLP Index. Every review is written by GLP Index Editorial and runs the same play: the same five dimensions, the same sources, checked and dated the same way — so a verdict means something and two reviews can be compared honestly. Our editorial policy covers the rules we write by; this page covers how the reviewing actually gets done.

How we review a provider

Every provider goes through the same six steps, in this order:

1. Map the offering. We pull the provider’s own published pricing, plans, and terms — the primary source, not a summary of it.
2. Work out the real price. We reduce the advertised numbers to an all-in monthly cost: membership plus medication plus any known fees. The advertised “from” price is almost never what you actually pay, and that gap is the first thing we surface.
3. Read the fine print. Subscription terms, cancellation and refund policies, and how the medication is sourced and compounded — the things that surprise people after they’ve signed up.
4. Check the record. Regulatory and legitimacy trail: FDA warning letters, state pharmacy-board licensing, LegitScript status, lawsuits, and the BBB profile. We disclose what we find, including when it’s unflattering.
5. Synthesize real user sentiment. We aggregate what actual customers report across Trustpilot, the Better Business Bureau, app stores, and Reddit — the recurring praise and the recurring complaints, with sources, not cherry-picked quotes.
6. Write the verdict, then re-verify. Only then do we write who a provider is genuinely a fit for and who should skip it — and we re-check the fast-moving details, pricing above all, on a set cadence.

What we evaluate

We judge every provider on the same five dimensions. Each one maps to a section of the review where you can see the evidence for yourself:

• Pricing & transparency. The real all-in monthly cost, what’s included versus what costs extra, how much doses cost as they increase, cancellation and refund terms, and how openly the provider publishes its prices in the first place. Sources: the provider’s published pricing and terms, dated.
• Medication options. Which GLP-1s are on the menu, compounded versus brand-name, dose flexibility, and whether a brand-name path exists for people who want one. Sources: the provider’s formulary and program pages.
• Care & clinician access. The care model (asynchronous messaging versus live video), who actually writes the prescription, response times, and how ongoing check-ins and dose changes are handled. Sources: the provider’s process pages and the real signup flow.
• Safety & sourcing. The named fulfilling pharmacy and its 503A/503B status, the regulatory record, how verifiable the provider’s legitimacy actually is, and whether they’re honest that compounded medications are not FDA-approved. Sources: the FDA database, state boards, LegitScript, the BBB, and court records.
• Customer experience. What real customers report over and over — billing surprises, refill and shipping reliability, and how responsive support is — synthesized across platforms, the good and the bad. Sources: Trustpilot, the BBB, app stores, and Reddit, cited.

These five are applied identically to every provider, which is what lets our reviews compare like for like. Pricing shows up in the cost section, Safety & sourcing in the “Is it legit?” section, and Customer experience in the user-reviews section — so nothing in the verdict is a claim you can’t trace back to evidence on the page.

How we verify what we publish

Legitimacy is verifiability, not vibes — the same standard we hold providers to, we hold ourselves to. Prices carry the date we checked them and get re-checked on a cycle. Claims are tied to primary sources, linked so you can follow them. And where we tell you a provider can be verified, we tell you how to do it yourself: look the pharmacy up on LegitScript or your state pharmacy board, search the FDA’s warning-letter database, and read the provider’s own cancellation terms before you pay. If you can’t check our work, we haven’t done our job.

What we don’t do

• We don’t use scores, stars, or letter grades. They compress judgment into false precision and, in this industry, they’re routinely traded for commissions. Every review ends in a plain-language verdict instead — here’s why.
• We don’t let anyone pay for a verdict, a better position, or a place in a roundup.
• We don’t seed or fabricate user reviews, invent star counts, or pass off made-up ratings as real customer sentiment.
• We don’t invent reviewers or rent a clinician’s name. A reviewer’s name appears only on work they’ve actually reviewed.
• We don’t publish AI-generated images of branded medications or fake product photos.
• We do review and name providers we have no affiliate relationship with — and we say so.

How we make money

GLP Index is free to read and takes no money from drugmakers. We earn affiliate commissions when readers sign up with some of the providers we link to, at no extra cost to you. The editorial call comes first; an affiliate link, where one exists, is attached after — never the other way around. The full breakdown lives on our editorial policy and partnerships pages.

Who writes and reviews this

GLP Index Editorial is the team that researches, writes, and maintains these reviews — a research desk built around GLP-1 pricing, telehealth, and regulatory sourcing, not a byline for hire. Every page crosses the desk of our founder, Spencer Lanoue, before it publishes; the buck stops there.

We’ll be straight about what we don’t have yet: GLP Index does not currently claim formal clinical review of its content. When a licensed clinician reviews a page, their name will appear on it — and never on anything they haven’t actually reviewed. We’d rather show an honest empty seat than rent a face.

Keeping reviews current

GLP-1 pricing, shortages, compounding rules, and regulatory news all move fast, and price is the fastest-decaying thing on any review. We re-verify pricing on a regular cycle — quarterly at a minimum, more often for the most-read providers — and bump a review’s “updated” date only when something material actually changed. When the facts move, we update the review rather than leave stale guidance up.

Corrections & feedback

If we’ve gotten something wrong, tell us and we’ll fix it — quickly, and without burying it. Use the contact form (choose “Correction or content feedback”) or email hello@glpindex.com. For the medications themselves, read our GLP-1 safety information and medical disclaimer — nothing here is medical advice.